SenzaGen AB (SENZA) - Total Liabilities
Based on the latest financial reports, SenzaGen AB (SENZA) has total liabilities worth Skr24.13 Million SEK (≈ $2.60 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of SenzaGen AB to track the company's year-over-year net asset growth rate.
SenzaGen AB - Total Liabilities Trend (2014–2024)
This chart illustrates how SenzaGen AB's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of SenzaGen AB to measure how efficiently the company converts operating cash flow to free cash.
SenzaGen AB Competitors by Total Liabilities
The table below lists competitors of SenzaGen AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Little Green Pharma Ltd
AU:LGP
|
Australia | AU$11.59 Million |
|
Securemetric Berhad
KLSE:0203
|
Malaysia | RM24.78 Million |
|
Leeuwin Metals Ltd
AU:LM1
|
Australia | AU$2.08 Million |
|
Climeon AB (publ)
ST:CLIME-B
|
Sweden | Skr31.28 Million |
|
Simris Alg AB (publ)
ST:SIMRIS-B
|
Sweden | Skr136.97 Million |
|
Firefly Neuroscience, Inc.
NASDAQ:AIFF
|
USA | $2.75 Million |
|
Wanted Lab Inc.
KQ:376980
|
Korea | ₩23.06 Billion |
|
EG Corporation
KQ:037370
|
Korea | ₩132.48 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down SenzaGen AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SenzaGen AB stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.94 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SenzaGen AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SenzaGen AB (2014–2024)
The table below shows the annual total liabilities of SenzaGen AB from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr25.27 Million ≈ $2.72 Million |
-14.55% |
| 2023-12-31 | Skr29.57 Million ≈ $3.18 Million |
-2.26% |
| 2022-12-31 | Skr30.25 Million ≈ $3.26 Million |
+28.40% |
| 2021-12-31 | Skr23.56 Million ≈ $2.54 Million |
+527.32% |
| 2020-12-31 | Skr3.76 Million ≈ $404.21K |
-57.07% |
| 2019-12-31 | Skr8.75 Million ≈ $941.53K |
+93.01% |
| 2018-12-31 | Skr4.53 Million ≈ $487.82K |
-40.86% |
| 2017-12-31 | Skr7.67 Million ≈ $824.88K |
+246.68% |
| 2016-12-31 | Skr2.21 Million ≈ $237.94K |
-40.95% |
| 2015-12-31 | Skr3.74 Million ≈ $402.91K |
+50.06% |
| 2014-12-31 | Skr2.50 Million ≈ $268.50K |
-- |
About SenzaGen AB
SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices;… Read more